eVusheld Assessment reaL wORld effectiveness in the VA Health System - VALOR-VA

Study identifier:D8850R00014

ClinicalTrials.gov identifier:NCT05663957

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

An Observational Study to Assess the Real-World Effectiveness of EVUSHELD™ (Tixagevimab/Cilgavimab) as Pre-exposure Prophylaxis Against COVID-19 Among EVUSHELD-eligible Populations Receiving Care in VA Health System in the United States

Medical condition

SARS-CoV-2, COVID-19

Phase

Phase 4

Healthy volunteers

Study drug

Evusheld

Sex

All

Actual Enrollment

5814

Study type

Observational

Age

12 Years - n/a

Date

Study Start Date: 04 Jan 2023

Primary Completion Date: 01 Sept 2023

Study Completion Date: 01 Sept 2023

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Aug 2024 by AstraZeneca

Collaborators

VA Informatics and Computing Infrastructure (VINCI)

Inclusion and exclusion criteria

Location

Research Site

Salt Lake City, UT, United States, 84148-0001

Arms	Assigned Interventions
EVUSHELD arm Individuals given EVUSHELD for prophylaxis	Drug: Evusheld EVUSHELD users
Concurrent Control arm Individuals eligible for Evusheld prophylaxis but did not receive EVUSHELD	-

"There is no result for the study"

Documents available

Redacted CSR Synopsis D8850R00014
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Clinical Study Information Center

1-877-240-9479

information.center@astrazeneca.com

Investigators

Principal Investigator

Scott L DuVall